Results for 'SB3'
Browse oncology articles matching SB3 — expert analysis, clinical perspectives, and industry updates from across drug development and care delivery. Use the tabs above for podcasts, press releases, partners, and people for the same search.
Mark Verrill, Paul Declerck, Sibylle Loibl, Jake Lee & Javier Cortes
The rise of oncology biosimilars: from process to promise
biologic, biosimilar, breast cancer, SB3, trastuzumab
Biosimilars are biologic products that are highly similar to the approved originator molecule, with no clinically meaningful differences. They are expected to play a key role in cancer treatment by reducing costs and improving access. Regulatory bodies use robust mechanisms for approval, involvi…
Aug 23rd • 18 mins read
David J. Segarnick, PhD Chief Medical Officer, Educational Resource Systems Adjunct Associate Professor, Rutgers New Jersey Medical School Department of Pharmacology, Physiology & Neuroscience David E. Wazer, MD, FACRO, FABS, FACR, FASTRO Research Scholar
From Genomic Testing to Digital Biomarkers: The Expanding Role of Biomarkers in Oncology
oncology biomarkers, precision oncology, predictive biomarkers
Biomarkers have moved from the margins of oncology to the center of clinical decision-making. They now help establish diagnosis and prognosis, identify patients most likely to benefit from targeted therapy or immunotherapy, monitor response, detect molecular residual disease and emerging resistance,…
Aug 20th • 35 mins read
Gregory S. Calip, PharmD, MPH, PhD, Ivy P. Altomare, MD, Jenny S. Guadamuz, MSPH, PhD
Evaluating External Validity of Oncology Biosimilar Safety Studies
biologics, external validity, FDA, biosimilars, trastuzumab
Biologics are the fastest growing medication class in the US, significantly contributing to healthcare costs. The Biologics Price Competition and Innovation Act of 2009 created an abbreviated approval pathway to make biological products more accessible. A phase 3 randomized trial of SB3, a trast…
Apr 6th • 2 mins read